Brought to you by 
Rigel partners alopecia areata candidates with Aclaris
01 Feb 2023
Executive Summary
Rigel Pharmaceuticals Inc. licensed Aclaris Therapeutics Inc. exclusive global rights to develop its preclinical Janus kinase (JAK) inhibitors for alopecia areata and additional dermatological diseases. The candidates are named ATI50001 and ATI50002.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Rigel partners alopecia areata candidates with Aclaris
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice